Literature DB >> 7517220

The nature of the B lymphocyte in B-chronic lymphocytic leukemia.

F Caligaris-Cappio1, D Gottardi, A Alfarano, A Stacchini, M G Gregoretti, P Ghia, M T Bertero, A Novarino, L Bergui.   

Abstract

We have analyzed phenotypic, functional, and molecular properties of B-chronic lymphocytic leukemia (B-CLL) cells as compared to normal B cell differentiation stages and/or subsets. The possibility that the target B cell population transformed by the I primary oncogenic event(s) belongs to the normal CD5+ B cell subset from B mantle zone of secondary follicles is highly likely on phenotypic grounds. Though the genes responsible for the primary oncogenic event are presently unknown, a number of functional and molecular findings indicate that the end-product of their transforming activity is a cell frozen in the G0 phase of the cell cycle. This cell has several abnormalities that prevent an appropriate mitogenic response and presents a pattern of apoptosis-related gene expression that hinders apoptotic death. Pivotal to this apoptosis-escaping capacity is the expression of Bcl-2. We suggest that the increased expression of Bcl-2 together with an asynchronism between the expression of Bcl-2, c-myc, and APO1/Fas gene products shift the cellular balance away from apoptosis thereby helping the progressive accumulation in G0 of malignant CD5+ B cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7517220

Source DB:  PubMed          Journal:  Blood Cells        ISSN: 0340-4684


  9 in total

1.  The synthesis of Bcl-2 and other proteins in the neoplastic follicles of follicular lymphoma.

Authors:  I A Lampert
Journal:  Mol Pathol       Date:  1999-02

Review 2.  Growth and survival of B-chronic lymphocytic leukaemia cells.

Authors:  O Söderberg
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

3.  Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.

Authors:  Rajesh Kumar Gandhirajan; Peter Anton Staib; Katharina Minke; Iris Gehrke; Günther Plickert; Axel Schlösser; Esther Katharina Schmitt; Michael Hallek; Karl-Anton Kreuzer
Journal:  Neoplasia       Date:  2010-04       Impact factor: 5.715

4.  Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins.

Authors:  Rashmi Gupta; Wentian Li; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2019-04-15       Impact factor: 5.422

5.  Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients.

Authors:  F Boissard; J-J Fournié; A Quillet-Mary; L Ysebaert; M Poupot
Journal:  Blood Cancer J       Date:  2015-10-02       Impact factor: 11.037

6.  BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells.

Authors:  Thomas Naves; Anne-Laure Fauchais; Marie-Odile Jauberteau; Hugo Talbot; Sofiane Saada; Elodie Barthout; Paul-François Gallet; Nathalie Gachard; Julie Abraham; Arnaud Jaccard; Danielle Troutaud; Fabrice Lalloué
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

7.  IL-10 Rescues CLL Survival through Repolarization of Inflammatory Nurse-like Cells.

Authors:  Marcin Domagala; Loïc Ysebaert; Laetitia Ligat; Frederic Lopez; Jean-Jacques Fournié; Camille Laurent; Mary Poupot
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

8.  Nurse-like cells impact on disease progression in chronic lymphocytic leukemia.

Authors:  F Boissard; C Laurent; A G Ramsay; A Quillet-Mary; J-J Fournié; M Poupot; L Ysebaert
Journal:  Blood Cancer J       Date:  2016-01-15       Impact factor: 11.037

9.  Nurse-like cells promote CLL survival through LFA-3/CD2 interactions.

Authors:  Loic Ysebaert; Mary Poupot; Frédéric Boissard; Marie Tosolini; Laetitia Ligat; Anne Quillet-Mary; Frederic Lopez; Jean-Jacques Fournié
Journal:  Oncotarget       Date:  2016-11-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.